Capricor Therapeutics, Inc. (CAPR)
6.71
-0.56
(-7.70%)
USD |
NASDAQ |
Oct 16, 16:00
6.73
+0.02
(+0.30%)
After-Hours: 20:00
Capricor Therapeutics Cash from Investing (Quarterly) : -48.76M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -48.76M |
| March 31, 2026 | -154.64M |
| December 31, 2025 | 43.09M |
| September 30, 2025 | 15.95M |
| June 30, 2025 | 14.55M |
| March 31, 2025 | 23.89M |
| December 31, 2024 | -123.38M |
| September 30, 2024 | 2.005M |
| June 30, 2024 | 14.70M |
| March 31, 2024 | -9.502M |
| December 31, 2023 | -5.863M |
| September 30, 2023 | 7.721M |
| June 30, 2023 | 6.461M |
| March 31, 2023 | -3.212M |
| December 31, 2022 | 5.142M |
| September 30, 2022 | -4.177M |
| June 30, 2022 | -35.41M |
| March 31, 2022 | -0.6254M |
| December 31, 2021 | -0.3687M |
| September 30, 2021 | -0.4682M |
| June 30, 2021 | -0.3225M |
| March 31, 2021 | -0.0369M |
| December 31, 2020 | -0.2881M |
| September 30, 2020 | -0.152M |
| June 30, 2020 | -0.1075M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.987M |
| December 31, 2019 | -5.987M |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 2.985M |
| December 31, 2018 | 3.005M |
| September 30, 2018 | -0.1426M |
| June 30, 2018 | -0.002M |
| March 31, 2018 | 1.812M |
| December 31, 2017 | -2.984M |
| September 30, 2017 | -1.014M |
| June 30, 2017 | 4.979M |
| March 31, 2017 | 4.001M |
| December 31, 2016 | -10.59M |
| September 30, 2016 | -0.0146M |
| June 30, 2016 | -0.0316M |
| March 31, 2016 | 5.449M |
| December 31, 2015 | 4.993M |
| September 30, 2015 | 2.415M |
| June 30, 2015 | -0.0233M |
| March 31, 2015 | -15.52M |
| December 31, 2014 | 0.3754M |
| September 30, 2014 | -0.0711M |
| June 30, 2014 | -0.069M |
| March 31, 2014 | -0.0943M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | 41.57M |
| SELLAS Life Sciences Group, Inc. | 0.00 |
| Sionna Therapeutics, Inc. | 21.47M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Cytokinetics, Inc. | -507.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -31.49M |
| Cash from Financing (Quarterly) | -4.243M |
| Free Cash Flow | -129.78M |
| Free Cash Flow Per Share (Quarterly) | -0.6454 |
| Free Cash Flow to Equity (Quarterly) | -107.31M |
| Free Cash Flow to Firm (Quarterly) | -37.39M |
| Free Cash Flow Yield | -36.85% |